Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Exagen Inc. (XGN)

2.44   0.01 (0.41%) 12-06 09:30
Open: 2.49 Pre. Close: 2.43
High: 2.44 Low: 2.44
Volume: 604 Market Cap: 40(M)

Technical analysis

as of: 2022-12-06 9:23:11 AM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 3.96     One year: 4.9
Support: Support1: 2.09    Support2: 1.74
Resistance: Resistance1: 3.39    Resistance2: 4.19
Pivot: 2.81
Moving Average: MA(5): 2.62     MA(20): 2.68
MA(100): 4.13     MA(250): 6.14
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 19.7     %D(3): 24.7
RSI: RSI(14): 43.9
52-week: High: 11.68  Low: 2.09
Average Vol(K): 3-Month: 89 (K)  10-Days: 204 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ XGN ] has closed above bottom band by 21.6%. Bollinger Bands are 22.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.51 - 2.53 2.53 - 2.54
Low: 2.25 - 2.28 2.28 - 2.3
Close: 2.39 - 2.45 2.45 - 2.48

Company Description

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Headline News

Fri, 02 Dec 2022
Exagen Inc. (XGN) Stock Price Today, Quote & News - Seeking Alpha

Mon, 28 Nov 2022
Where Does Exagen Inc (XGN) Stock Fall in the Diagnostics & Research Field After It Is Lower By -2.04% This Week? - InvestorsObserver

Wed, 23 Nov 2022
Healthcare Stocks Making Moves Wednesday: NRBO, NMTC, XGN, GLSI, BIOL, PRE, JUPW, CCCC - InvestorsObserver

Wed, 16 Nov 2022
Healthcare Stocks Moving Wednesday: INM, ENSC, FIXX, XGN, BKD, PEAR, PALI, NBY - InvestorsObserver

Mon, 14 Nov 2022
Exagen Inc. (XGN) Q3 2022 Earnings Call Transcript - Seeking Alpha

Mon, 17 Oct 2022
Exagen Names Aballi President, CEO as Rocca Steps Down >XGN - MarketWatch

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 16 (M)
Shares Float 7 (M)
% Held by Insiders 21.2 (%)
% Held by Institutions 76.2 (%)
Shares Short 20 (K)
Shares Short P.Month 35 (K)

Stock Financials

EPS -1.83
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.45
Profit Margin (%) -88.3
Operating Margin (%) -83.3
Return on Assets (ttm) -20.7
Return on Equity (ttm) -54.6
Qtrly Rev. Growth 20.2
Gross Profit (p.s.) 1.7
Sales Per Share 2.79
EBITDA (p.s.) -2.25
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -1.34
PEG Ratio 0
Price to Book value 0.7
Price to Sales 0.87
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.